Clinical Effects and Safety of the Use of Methylene Blue for the Treatment of Lumbar Facet Joint Syndrome

What Was Tested

This randomized controlled trial paper looks at Methylene blue (non-peptide stack partner).

The purpose of this study was to evaluate the therapeutic effects of intra-articular injection of MB on LFJS patients.

Numeric Rating Scale (NRS), Oswestry Disability Index (ODI), Pittsburgh Sleep Quality Index (PSQI), Patient Health Questionnaire-9 (PHQ-9) were used to evaluate the pre-operation and post-operation states of the patients, and adverse events were recorded.

Why It Was Studied

Methylene blue (MB), an inhibitor of nitric oxide synthesis with potential analgesic and anti-inflammatory properties, has been widely applied for a variety of pain-related diseases.

However, no studies have been conducted on the treatment of LFJS patients using MB.

Who Took Part

According to the abstract, 120 patients were involved.

Department of pain, Shanghai East Hospital.

A total of 120 eligible patients with LFJS were randomly divided into an MB group and a control group.

How the Study Was Run

The design is described as randomized and double-blind.

Random assignment meant chance, not the researchers, decided who got Methylene blue (non-peptide stack partner) and who got the comparison, which limits bias.

As a double-blind Methylene blue (non-peptide stack partner) study, the assignments were hidden from both participants and investigators until the end.

The timeline in the abstract includes 6 months.

A prospective, randomized, controlled clinical trial.

The patients participating in this study were followed up for a period of 6 months.

Firstly, the patients enrolled were recruited from a single center, and the sample size was small.

What Was Measured

The subject headings attached to it are China, Injections, Intra-Articular, Low Back Pain, Methylene Blue and Zygapophyseal Joint.

Author keywords: intra-articular injection, ultrasound guidance and Facet joint syndrome.

What This Means in Plain Language

The paper is a randomized and double-blind study of Methylene blue (non-peptide stack partner) in 120 patients over 6 months.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (Pain physician), a journal based in United States.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.